Advances in pharmacotherapy for primary biliary cirrhosis. - Wikidata - wikimedia - TriplyDB

Advances in pharmacotherapy for primary biliary cirrhosis.

Advances in pharmacotherapy for primary biliary cirrhosis.

http://www.wikidata.org/entity/Q36116022

about

Xenobiotics and loss of tolerance in primary biliary cholangitis Genetic Polymorphisms of Cytotoxic T-Lymphocyte Antigen 4 in Primary Biliary Cholangitis: A Meta-Analysis Quantitation of the Rank-Rankl Axis in Primary Biliary Cholangitis.Pro-tumoural CXCL10/CXCR3-A autocrine loop in invasive mucinous lung adenocarcinoma.Emerging drugs for the treatment of Primary Biliary Cholangitis.Primary Biliary Cholangitis: Disease Pathogenesis and Implications for Established and Novel Therapeutics.Chronic Autoimmune Epithelitis in Sjögren's Syndrome and Primary Biliary Cholangitis: A Comprehensive Review.Complications, symptoms, quality of life and pregnancy in cholestatic liver disease.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Primary biliary cholangitis: new treatments for an old disease.Obeticholic Acid: A Farnesoid X Receptor Agonist for Primary Biliary Cholangitis.

P2860

Q26772312-42D2BB0F-A713-4671-A7EA-82E3D4849FBE Q33795082-93331A8C-1BE8-410F-A8A7-48FD433CBAE0 Q36134061-30DCE296-F9B7-4377-AE8B-383E488AC46C Q38694064-902819BC-36B9-407F-ADB5-D7C882EC113A Q38744215-2E07A899-4AC2-43D7-A0B4-E1A7CF41AB2A Q39047912-FDBD0E06-DA88-4B1A-978C-7AD28EDEDA03 Q47146987-31E5DD7E-A5FA-4507-9D2F-6A9ADAFA61D3 Q48331749-91CEF569-E054-4053-B62A-1FF27D2982BF Q50136712-3A3E694C-EE1F-4D1E-A09E-CECF3DD2F147 Q54390436-0C5F439A-2963-4A05-AE40-B5748615FB74 Q55165714-41C3C068-BC02-4BC1-8A25-1F59E91FB400

P2860

Advances in pharmacotherapy for primary biliary cirrhosis.

http://www.wikidata.org/entity/Q36116022

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Advances in pharmacotherapy for primary biliary cirrhosis.

@ast

Advances in pharmacotherapy for primary biliary cirrhosis.

@en

type

label

Advances in pharmacotherapy for primary biliary cirrhosis.

@ast

Advances in pharmacotherapy for primary biliary cirrhosis.

@en

prefLabel

Advances in pharmacotherapy for primary biliary cirrhosis.

@ast

Advances in pharmacotherapy for primary biliary cirrhosis.

@en

P1433

Q36116022-68D6E233-345B-4F85-817D-AAEC33AFD454

P1476

Q36116022-16A8CD60-19C8-46BD-9843-C983992FB727

P2093

Q36116022-67D0A3CF-B1CE-46F8-B477-FC2F794DE25B

Q36116022-73CBF99A-1C6A-4FEE-B276-EDFD35327042

P2860

Q36116022-00558CEA-1268-4314-8DBD-F08605A32EF8

Q36116022-00758AE0-40A4-4E62-B168-FA16B5D7035A

Q36116022-03B3FD2D-3324-476A-87BF-D3CA0E77341D

Q36116022-09FBAA3B-D713-4CC6-AC07-F91F39C7E7D1

Q36116022-0B33ADC1-E3AA-4411-8CFE-3B20C746FEC2

Q36116022-0B95B674-03AB-4D07-90DE-7BD82F26778D

Q36116022-0C0E6F4C-C2AF-4FE3-A765-2E4CAA22CE29

Q36116022-0E7989F0-8342-4717-82AF-434F5C30DC38

Q36116022-11AE78BA-AF72-45A4-87CA-727E8B464456

Q36116022-130F8E19-0C6E-42A2-80EA-3A795AFE1442

P304

Q36116022-F9ACEF7F-ED00-4E44-A018-B8C1A70602FE

P31

Q36116022-2576EB10-B1EE-4D6B-B2BC-5A01741532C6

P356

Q36116022-48F19FAD-E868-4EAD-9F14-08EFC6705B02

P407

Q36116022-8BB40BA8-AB4C-44F9-B3DA-9BE1891F5AF9

P433

Q36116022-0DA240D3-634C-4F52-9EDB-18A9DC293973

P478

Q36116022-BC81A472-C3BF-4791-9081-CB01F4034BAD

P50

Q36116022-927A6E1C-F73E-4A36-9F3C-1794FE63A39D

Q36116022-D5401719-72A0-4F37-A684-330F40152677

Q36116022-E966D1B1-04DA-4D7D-8E93-A0C93C382A31

P577

Q36116022-E3449E2A-ED9C-40DF-BA37-EDC1EB3366BE

P698

Q36116022-1FD71619-EA92-425A-B47C-BC29FAD61E03

P921

Q36116022-7491DEC1-7818-4970-B816-C81E4FC089B9

P932

Q36116022-103E016B-24E9-4458-8D4B-31F19C99A65B

P356

14656566.2015.998650

P1433

Expert Opinion on Pharmacotherapy

P1476

Advances in pharmacotherapy for primary biliary cirrhosis.

@en

P2093

Christopher L Bowlus

http://www.w3.org/2001/XMLSchema#string

Merril Eric Gershwin

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants

Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management

Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease

Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17

Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents

Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response

Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis

Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain

P304

633-643

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.2015.998650

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Pietro Invernizzi

P577

2014-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25543678

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy

P932

4591873

http://www.w3.org/2001/XMLSchema#string